All News
Filter News
Found 806,258 articles
-
Implant Helps Control Snoring, Swedish Sleep Center Study
7/22/2011
-
Human Genome Sciences, Inc. Reports $7.8M In Benlysta Sales
7/22/2011
-
FDA Clears 22nd Century Group, Inc.'s X-22 IND For Phase II-B Smoking Cessation Clinical Trial
7/22/2011
-
Sapheon Completes Enrollment in 30-Patient Study of Novel Vein Disease Treatment
7/22/2011
-
Northwest Biotherapeutics Releae: Cleveland Area Brain Cancer Patients Now Testing Revolutionary Personalized Immune Therapy for Cancer
7/22/2011
-
St. Jude Children's Research Hospital Release: Signaling Molecule Identified As Essential For Maintaining a Balanced Immune Response
7/22/2011
-
New Publication Validates StemCells Inc.'s SC Proven(R) Reagents for Automated Production and Cell-Based Screening
7/22/2011
-
Express Scripts Inc. Buying Medco Health Solutions, Inc. for $29.1 Billion, Looking to Limit Costs
7/22/2011
-
BrainStorm Cell Therapeutics Inc. Enters Into Agreement with FDA Specialist, PharmaNet, Inc., for the Development of ALS Human Clinical Trial Protocol in the USA
7/22/2011
-
Agilent Technologies Inc. and A*STAR's Experimental Therapeutics Center Launch All-in-One Drug-Screening Platform at Singapore Screening Center
7/22/2011
-
Tianyin Pharmaceutical Co, Inc. Ships Macrolide API Samples for International Sales Standard Testing
7/22/2011
-
IlluminOss Medical Inc. Announces US Notice of Allowance
7/22/2011
-
Ortho Clinical Diagnostics Launches VITROS 4600® Chemistry System for Mid- to High-Volume Laboratories
7/22/2011
-
SynergEyes, Inc. Release: ClearKone® Prescribed to More than 16,000 Patients in 32 Countries
7/22/2011
-
Sigma® Life Science Launches Genetically Modified Human Cell Lines for Breast Cancer Research
7/22/2011
-
Rosetta Genomics Ltd. Regains Compliance With NASDAQ Minimum Bid Price Rule
7/22/2011
-
Cardio Infrared Technologies, Inc. Provides Update on DTC Eligibility of Its Securities
7/22/2011
-
Australian Anti-Cancer Company Immune System Therapeutics Limited Completes $2.6 Million Placement
7/22/2011
-
Pernix Therapeutics, Inc. Announces Pricing of $28 Million Underwritten Registered Direct Offering of Common Stock
7/22/2011
-
AspenBio Pharma, Inc. to Maintain NASDAQ Listing With Reverse Split of Common Stock
7/22/2011